Inactive Instrument

MetaStat Inc Share Price OTC Bulletin Board

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

21/06/18	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
03/08/17	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI

MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.

Employees

Sector

Biotechnology & Medical Research

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Market Cap	529K 455K 428K 391K 732K 49.94M 734K 5.06M 1.96M 25.62M 1.99M 1.94M 82.55M	P/E 2017	-0.72x	P/E 2018	-2.02x
Enterprise Value	1.21M 1.04M 981K 896K 1.68M 114M 1.68M 11.6M 4.5M 58.71M 4.55M 4.45M 189M	EV / Sales 2017	-	EV / Sales 2018	329,023,519x
Free-Float	98.43%	Yield 2017 *	-	Yield 2018	-

21/06/18	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
03/08/17	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI
02/08/17	MetaStat, Inc. announced that it has received $2.57 million in funding	CI
22/06/17	MetaStat, Inc. announced that it expects to receive $7 million in funding	CI
19/06/17	MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation	CI
31/05/17	MetaStat, Inc. Appoints Paul Billings to its Board of Directors, Effective as of May 24, 2017	CI
08/05/17	MetaStat, Inc. Announces Management Changes	CI
08/05/17	MetaStat, Inc. Announces Board Changes	CI
28/04/17	MetaStat, Inc. Announces Resignation of Martin J. Driscoll from the Board of Directors	CI
06/04/17	MetaStat, Inc. Presents Supportive Data for the Role of Mena Protein Isoforms in Tumor Dissemination at the 2017 American Association of Cancer Research Annual Meeting	CI
19/12/16	MetaStat, Inc. Receives Additional State Clinical Laboratory Licenses	CI
13/12/16	MetaStat, Inc. Presents Positive Data from Two Clinical Studies of Metasite Breast at 2016 San Antonio Breast Cancer Symposium	CI
20/10/16	MetaStat, Inc. announced that it has received $2.61 million in funding	CI

Director	Title	Age	Since
Douglas A. Hamilton BRD	Director/Board Member	59	03/05/2017
Paul Billings BRD	Director/Board Member	73	23/05/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-1.18%	-2.84%	-1.77%	+14.33%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+46.82%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	16.5B
EUROFINS SCIENTIFIC SE	-0.88%	-0.44%	+12.98%	+32.27%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	13.77B
Average	-0.71%	+0.53%	+73.94%	+110.31%	30.55B
Weighted average by Cap.	-0.74%	+0.11%	+89.37%	+129.00%

	2017	2018
Net sales	-	0.02 0.02 0.02 0.02 0.03 2.2 0.03 0.22 0.09 1.13 0.09 0.09 3.64
Net income	-2.94M -2.53M -2.38M -2.18M -4.07M -278M -4.08M -28.14M -10.92M -142M -11.05M -10.8M -459M	-3.18M -2.74M -2.58M -2.35M -4.4M -300M -4.41M -30.43M -11.81M -154M -11.95M -11.68M -496M
Net Debt	206K 178K 167K 153K 286K 19.49M 286K 1.97M 766K 10M 775K 758K 32.21M	683K 588K 553K 505K 945K 64.49M 948K 6.53M 2.54M 33.09M 2.56M 2.51M 107M

MetaStat Inc Share Price OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation : MetaStat Inc

Latest news : MetaStat Inc

Managers and Directors : MetaStat Inc

Other Biotechnology & Medical Research

Financials

Company Profile